Suchergebnisse - "Schmid, Peter"

PubPharm (22)

1

Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer : exploratory analysis from KEYNOTE-119

enthalten in: The journal of pathology. Clinical research | 2024

von Cortes, J. | Winer, E. | Lipatov, O. | +18

2

First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer : Clinical and Biomarker Results

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Schmid, P. | Turner, N. | Barrios, C. | +25

3

Prognostic and predictive impact of gene expression in node-positive early breast cancer patients receiving dose-dense versus standard-dose adjuvant chemotherapy

enthalten in: Molecular oncology | 2023

von Reinisch, M. | Bruzas, S. | Gluz, O. | +12

4

Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer : KEYNOTE-086 Exploratory Analysis

enthalten in: JCO precision oncology | 2023

von Loi, S. | Salgado, R. | Schmid, P. | +20

5

Evaluation of triple negative breast cancer with heterogeneous immune infiltration

enthalten in: Frontiers in immunology | 2023

von Quintana, �. | Arenas, E. | Bernadó, C. | +10

6

PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer

enthalten in: Journal of the National Cancer Institute | 2021

von Rugo, H. | Loi, S. | Adams, S. | +14

CommentIn: J Natl Cancer Inst. 2021 Nov 29;113(12):1613-1614. - PMID 34097056

7

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain) : a multicentre, randomised, open-label, non-comparative, phase 2 trial

enthalten in: The Lancet. Oncology | 2021

von Pérez-García, J. | Gebhart, G. | Ruiz Borrego, M. | +20

CommentIn: Future Oncol. 2022 Oct;18(33):3677-3688. - PMID 36300423

8

Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Quintana, �. | Peg, V. | Prat, A. | +15

9

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

enthalten in: Breast cancer research : BCR | 2021

von Schmid, P. | Sablin, M. | Bergh, J. | +17

10

A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Robertson, J. | Evans, A. | Henschen, S. | +24